Nipro (5FA) Stock Overview
Engages in the medical devices, pharmaceuticals, and pharma packaging businesses. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
5FA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Nipro Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥8.25 |
| 52 Week High | JP¥9.25 |
| 52 Week Low | JP¥7.50 |
| Beta | -0.012 |
| 1 Month Change | -8.33% |
| 3 Month Change | -4.07% |
| 1 Year Change | 7.84% |
| 3 Year Change | 27.91% |
| 5 Year Change | -19.12% |
| Change since IPO | -14.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5FA | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -1.2% | -1.6% | -1.6% |
| 1Y | 7.8% | -28.9% | -1.3% |
Return vs Industry: 5FA exceeded the German Medical Equipment industry which returned -28.5% over the past year.
Return vs Market: 5FA exceeded the German Market which returned -2.1% over the past year.
Price Volatility
| 5FA volatility | |
|---|---|
| 5FA Average Weekly Movement | 4.6% |
| Medical Equipment Industry Average Movement | 6.0% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 5FA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 5FA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1947 | 38,593 | Yoshihiko Sano | www.nipro.co.jp |
Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses. Its Medical-Related business develops, manufactures, and sells injection and infusion products, artificial organ-related products, functional products, dialysis products, cell cultures, hospital products, diabetic products, and pharmaceuticals comprising generic and kit products; and manufactures medical equipment, including dialysis medical device products; and operates dialysis and training centers. The company’s Pharmaceutical-Related business engages in the contract manufacturing of pharmaceutical products with containers for combination products, including injectable kit products consigned by other pharmaceutical companies; and provides injectable, oral drugs products.
Nipro Corporation Fundamentals Summary
| 5FA fundamental statistics | |
|---|---|
| Market cap | €1.37b |
| Earnings (TTM) | €72.77m |
| Revenue (TTM) | €3.56b |
Is 5FA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5FA income statement (TTM) | |
|---|---|
| Revenue | JP¥660.54b |
| Cost of Revenue | JP¥452.26b |
| Gross Profit | JP¥208.28b |
| Other Expenses | JP¥194.78b |
| Earnings | JP¥13.50b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 10, 2026
| Earnings per share (EPS) | 82.80 |
| Gross Margin | 31.53% |
| Net Profit Margin | 2.04% |
| Debt/Equity Ratio | 182.9% |
How did 5FA perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/09 07:08 |
| End of Day Share Price | 2026/07/09 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nipro Corporation is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Masahiro Nakanomyo | Barclays |
| Yuki Yamazaki | Daiwa Securities Co. Ltd. |
| Stephen Barker | Jefferies LLC |